Advertisement
Learn about featured cancer clinical trials currently enrolling, or search our cancer clinical trials database for all open and accruing studies
Breast
Phase III study evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
GBG 1115 | 15-1373
View full trial information.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Esophageal
A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel
HCP 2215 | 031520C
View full trial information.
Pancreas
A Phase II Study of Second-Line Therapy with Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
CASE 5214 | 15-166
View full trial information.
Renal
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (Msb0010718c) In Combination With Axitinib (Inlyta®) Versus Sunitinib (Sutent®) Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma
PFIZ 2816 | 16-573
View full trial information.
Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors
GITR 1Y15 | 101506C
View full trial information.
Myelodysplastic Syndrome (MDS)
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo For the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions
CLGN 2915 | 16-462
View full trial information.
Lymphoma, Diffuse Large B Cell
A Phase I/II Study of Carfilzomib in Combination with R-CHOP (CR-CHOP) for Patients with Diffuse Large B -Cell Lymphoma
CASE 3413 | 14-256
View full trial information.
Advertisement
Advertisement
Obstructing key protein allows for increased treatment uptake for taxane chemotherapy
Oral medication reduces epistaxis and improves quality of life for patients with rare vascular disorder
Findings could help with management of a common, dose-limiting side effect
Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression
Treatment involved checkpoint inhibitor, surgery and intravesical therapy
Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials
Multi-specialty coordination essential for improving quality of life